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http://dx.doi.org/10.1016/j.kjms.201Abstract Asthma is a chronic inflammatory disorder of the airway, characterized by airway
hyperresponsiveness. It is a disabling disease with an increasing prevalence, resulting in heavy
social and economic burdens worldwide. Humans are extensively exposed to phthalates, and
many epidemiological studies have shown a relationship between phthalate exposure and
asthma in recent decades. Earlier experimental studies focused on inflammatory cells, demon-
strating the adjuvant effects, immunomodulatory effects, or immunosuppressive effects
related to phthalate exposure. Recent studies have shown that phthalates may have a direct
effect on airway epithelial cells and contribute to airway remodeling, which is the cardinal
pathologic characteristic of chronic asthma, with a high correlation with disease severity.
Through these efforts, phthalates have been recognized as important environmental factors
in the pathogenesis of asthma, but further studies are still required to elucidate the detailed
mechanism. This review discusses the current status of human exposure to phthalates in
Taiwan and summarizes the epidemiological and experimental evidence related to the roles
of phthalate exposure in the development of asthma and associated diseases.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Clinical Medicine, College of
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vier Taiwan LLC. All rights reserv
2.05.007Introduction
Asthma is a chronic inflammatory disorder of the airway
with an increasing prevalence worldwide over the past few
decades. It is also an expensive disease, and has aroused
significant public health concern. Airway remodeling is the
cardinal pathological characteristic of chronic asthma, and
the degree of airway remodeling correlates well with
disease severity. In recent years, plasticizers, especiallyed.
Phthalate and asthma S29phthalates, have been recognized as important environ-
mental factors in the pathogenesis of asthma. Besides many
epidemiological studies showing a relationship between
phthalate exposure and asthma in recent decades, many
experimental studies have demonstrated various adjuvant
or inflammatory responses of inflammatory cells related to
phthalate exposure. Recent studies have shown that
phthalates may also contribute to airway remodeling.
The Taiwan plasticizer scandal in 2011 re-aroused
concern regarding the health effects of phthalates world-
wide, and it is therefore time to re-examine the evidence
concerning the health effects of exposure to phthalates.
This review focuses on the roles of phthalate exposure in
the development of asthma and associated diseases.
Phthalates
Phthalates, or phthalate esters, are esters of phthalic acid
(Fig. 1). Since the introduction of phthalates as plasticizers
in early 20th century, these industrial chemicals have
become the most widely used plasticizers, which are added
to plastics to increase their flexibility, transparency, dura-
bility, and longevity. The most commonly used phthalates
are di-(2-ethylhexyl) phthalate (DEHP), di-isononyl phtha-
late (DiNP), and di-isodecyl phthalate (DiDP) [1,2].
Human exposure to phthalates
Humans have extensive exposure to phthalates nowadays,
as these chemicals are the main plasticizers for polyvinyl
chloride (PVC), one of the most important plastic materials
[3e5]. Phthalates are ubiquitously present in our daily life,
being present in flexible plastics, toys, food packages,
pharmaceutical pills, paints, personal care products,
cosmetics, PVC flooring, and so on [6]. Because phthalates
are not chemically bound to the PVC molecules in plastics,Figure 1. Common phthalates. Abbreviations: BBzP, butyl-benzy
bis(2-ethylhexyl) phthalate (BEHP) or di-octyl phthalate (DOP)]; DE
decyl phthalate; DiHP, di-iso-hexyl phthalate; DiNP, di-iso-nonyl phtthey can easily leach out and evaporate into food or the
environment [7]. Ingestion is traditionally believed to be
the major route of exposure, although other routes,
including inhalation, dermal, and parenteral routes, have
also been recognized [1].
As DEHP is the phthalate plasticizer used in almost all PVC
medical devices, leaching of DEHP from PVC medical devices
and ultimate tissue deposition have been documented since
the late 1960s [6,8,9]. For example, DEHP has been detected
in the air delivered by PVC tubing used in respiratory
therapy [10]. It has also been reported that the quantity of
DEHP delivered to the patient from physiologic saline solu-
tion contained in a plastic PVC bag was 0.126 mg/L,
increasing to 0.588 mg/L after shaking [11]. Other medical
devices that may contain DEHP include intravenous bags and
tubing, catheters, blood bags and infusion tubing, enteral
nutrition feeding bags, nasogastric tubes, peritoneal dialysis
bags, and tubing used in cardiopulmonary bypass proce-
dures, extracorporeal membrane oxygenation, and during
hemodialysis [9].Current human exposure to phthalates
in Taiwan
Exposure to phthalates is usually quantified by detecting
urinary phthalate metabolites. A Taiwanese study revealed
that more than 90% of samples from 60 subjects contained
detectable monomethyl phthalate, mono-n-butyl phthalate
(MnBP), and mono-(2-ethylhexyl) phthalate (MEHP) [12].
Estimated from the quantities of urine metabolites, the
medium daily intake of DEHP in the Taiwanese subjects was
0.0339 mg/kg/day, which is about three times that repor-
ted in a German study [12e14]. Based on these data, 85% of
the subjects had an estimated daily intake of DEHP over the
reference dose of the United States Environmental
Protection Agency (0.02 mg/kg/day), and 37% of subjectsl phthalate; DEHP, di-(2-ethylhexyl) phthalate [also known as
P, di-ethyl phthalate; DiBP, di-iso-butyl phthalate; DiDP, di-iso-
halate; DnBP, di-n-butyl phthalate; DnOP, di-n-octyl phthalate.
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defined by the European Union Scientific Committee for
Toxicity, Ecotoxicity and the Environment in 1998
(0.037 mg/kg/day) [12]. In another study, a high content of
phthalate metabolites was detected in urine samples
collected from pregnant Taiwanese women, and the
median levels of MnBP, monoethyl phthalate, and MEHP
were 81.8 ng/ml, 27.7 ng/ml, and 20.6 ng/ml, respectively
[15].
Taiwan plasticizer scandal in 2011
In May 2011 the largest food scandal in Taiwan was repor-
ted. Initially, a quality inspector discovered that the
density of plasticizer in some raw materials of probiotics far
surpassed the standard in a routine check [16]. Further
investigation revealed that DEHP and DiNP were inappro-
priately used as cloudy agents instead of palm oil by some
food manufacturers to lower costs and prolong preservation
time [17e20]. This news generated worldwide attention,
and the Taiwanese government soon initiated seizures of
contaminated foods, including beverages, breads, and
jams, and announced a ban from exporting [19e23]. The
products were all recalled, examined, and immediately
destroyed [16,19,20,24]. This scandal highlighted the issue
of food safety and aroused the public’s attention with
regards to the health effects of phthalates.
Phthalates association with asthma
Asthma is a chronic inflammatory disorder of the airways.
Epidemiologic studies usually rely on questionnaire assess-
ments of symptoms, clinical diagnosis by physicians, and
the use of related medications. Although highly sensitive
and specific diagnostic tests are currently unavailable,
there is no doubt that asthma is a serious public health
problem worldwide, with an estimated 300 million affected
individuals, including people in all age groups [25]. The
prevalence varies widely between countries, ranging from
1% to 18% of the population, which may be partially
attributed to the lack of a precise and universally accepted
definition [25e29]. Nonetheless, the prevalence has been
rising in most parts of the world over the past few decades
[25e27,29].
Asthma is a costly illness. A national survey in the United
States for the years 2002e2007 showed that the estimated
total cost (in 2009 US dollars) of asthma to society,
including medical expenses ($50.13 billion per year in
2007), loss of productivity resulting from missed school or
work days ($3.76 billion per year in 2007), and productivity
loss due to death ($2.15 billion per year in 2007), was $56
billion in 2007, a $3 billion (5.7%) increase from 2002, and
the estimated medical expenses associated with asthma
were $3,259 per person per year (in 2009 US dollars)
[26,30]. Another study showed that adults with asthma
experienced higher healthcare use and comorbidity and
incurred an additional cost of $1,907 (in 2008 US dollars)
annually [31,32]. Although most patients with asthma can
be asymptomatic under appropriate medical control, some
patients have poorly-controlled asthma, which may result
in increased emergency department visits, hospitalizations,and medical costs [26,30]. In addition, about 4000 deaths
per year in the United States are attributed to asthma [30].
Therefore, the costs of asthma are substantial, necessi-
tating further research in this field.
Asthma is a complex disease resulting from interaction
between host factors and environmental factors. A variety
of risk factors have been identified, including genetic
susceptibility, obesity, gender, infections, atopy, tobacco
smoke, occupational sensitizers, air pollution, and other
environmental exposure [25].
The major clinical features of asthma include airway
inflammation, airway hyper-responsiveness, mucus hyper-
secretion, and intermittent reversible airway obstruction
[33,34]. Patients with asthma usually present with
repeated, variable, intermittent attacks of breathlessness,
cough, wheezing, or chest tightness as a result of inter-
mittent bronchoconstriction in the setting of airway hyper-
responsiveness and mucous hypersecretion [33].
Airway remodeling is the cardinal pathological charac-
teristic of chronic asthma, and the degree of airway
remodeling correlates well with disease severity [35e38].
Many cells and cellular elements play a role. The structural
changes in airway remodeling include loss of epithelial
integrity (epithelial cell erosion), subepithelial fibrosis,
goblet cell hyperplasia/metaplasia, submucosal gland
enlargement, airway smooth muscle hyperplasia and
hypertrophy, and microvascular changes (increased angio-
genesis mostly) [39e42]. These changes may result from
repeated or continuous airway inflammation induced by
repeated exposure to the allergen [34,43].
The role of phthalate exposure in the
development of asthma
Although phthalate exposure has been traditionally thought
to occur mostly through ingestion, other routes, including
dermal, parenteral, and particularly inhalation, may also
play important roles [1,44,45]. Much evidence, including
case reports, case series, epidemiologic studies, and
mechanistic toxicology studies, has demonstrated that
phthalate emissions from PVC materials may increase the
risk of asthma and allergies [1,44,45].
Epidemiologic evidence
In the 1970s, cases of asthma with possible relationships
with fumes from hot-wire cutting of PVC film or from
thermo-activated price labels were reported as “meat-
wrapper’s asthma” [46e49]. This led to several epidemio-
logic studies, which found that exposure may be associated
with a higher prevalence of asthma, allergy, or related
respiratory symptoms [50e54]. Some studies even found
that exposure was associated with decline in lung function
[50,52], while others showed no significant change [53,54].
Later, cases of asthma with a possible relationship with
occupational exposure to di-n-octyl phthalate (DnOP),
smoke inhalation from a residential fire, or exposure to
unheated PVC resin dust were also reported [55e57]. A
cohort study showed that firefighters exposed to burning
PVC had more frequent and severe respiratory symptoms
[58]. An observational study in a PVC processing plant found
Phthalate and asthma S31that workers exposed to PVC thermal degradation products
and phthalic acid esters had more upper airway symptoms
than unexposed workers, while no significant differences in
lung function were noted [59]. A study involving four
Swedish geriatric hospitals showed that asthma symptoms
may be associated with increased humidity in concrete
floor constructions and emission of 2-ethyl-1-hexanol (2-
EH), an indicator of dampness-related degradation of
DEHP [60]. A later study in an office building with severe
dampness and 2-EH in indoor air found that the workers’
respiratory symptoms and need for medications decreased
after interventions, including careful removal of the
plastic floor covering [61]. In a population-based incident
caseecontrol study systematically recruiting all new cases
of asthma during a 2.5-year-study period and randomly
selected controls in Finland, the risk of asthma was found
to be related to the presence of plastic wall materials and
wall-to-wall carpets at work [62].
There have also been many epidemiological studies in
children. Since the late 1990s, epidemiological studies
regarding the possible relationship between phthalates and
airway diseases in children have been conducted, mostly in
northern Europe. The presence of PVC materials, especially
PVC flooring, has been associated with bronchial obstruc-
tion in children in caseecontrol studies [63,64]. Subse-
quent cross-sectional questionnaire investigations also
showed significant associations between PVC flooring or
plastic wall material and airway symptoms in children
[65e67]. Later caseecontrol studies further demonstrated
that the concentration of DEHP in indoor dust was signifi-
cantly associated with case status and asthma [68,69].
Recently, in a large cohort study in Sweden, parental
reporting indicated that PVC flooring in the child’s and
parents’ bedroom when the child was aged 1 year to 3
years was significantly associated with incidence of asthma
5 years later [70].
These epidemiologic studies provide evidential clues
indicating a relationship between phthalate exposure and
asthma.Mechanistic toxicologic evidence e in vivo studies
Studies addressing the putative ability of phthalates to act
as adjuvants for immune responses have been investigated
almost exclusively in murine models, especially BALB/c
mice (mouse strain most susceptible to the development of
IgE-mediated reactions) [1,2,44]. Immune responses
underlying the development of allergic sensitization
involving antigen-presenting dendritic cells, Th2 cells, mast
cells, and eosinophils, and the production of specific IgE,
are hallmarks of allergic asthma [1,2,44]. In mice, Th2 cells
promote IgG1 and IgE, and Th1 cells promote IgG2a [44].
Because specific IgE is difficult to measure accurately due
to its presence in small amounts, the total plasma level of
IgE or IgG1 is commonly used as a surrogate marker [2,44].
However, although IgG1 is produced through similar mech-
anisms, the IgG1 level does not always exactly mirror the
IgE responses, so careful interpretation of the data is
required [2].
The adjuvant properties of phthalates appear to be
influenced markedly by the administration route and thetype and dose of the tested compound [1,2,44]. In initial
studies, phthalates were administered by subcutaneous
injection [71e74]. Subcutaneous exposure to DEHP effec-
tively augmented the antibody response of IgG1, but not
IgE, to ovalbumin [71]. When various monoesters (the
primary hydrolytic metabolites of phthalate diesters),
including MEHP, mono-n-octyl phthalate (MnOP), mono-iso-
nonyl phthalate (MiNP), mono-iso-decyl phthalate (MiDP),
mono-benzyl phthalate (MBnP), and MnBP, were tested,
various effects were observed: an immuno-suppressive
effect was observed with MEHP (1000 mg/ml, IgE and
IgG1), MnOP (1000 mg/ml, IgE and IgG1), MiNP (1000 mg/ml,
IgE and 10 mg/ml, IgG1) and MiDP (100 mg/ml, IgE and IgG1);
an adjuvant effect was observed with MEHP (10 mg/ml, IgE),
MnOP (100 mg/ml, and 10 mg/ml, IgG1) and MiNP (100 mg/
ml, IgE); and no statistically significant immune modulating
effect was seen with MBnP and MnBP [72]. Similar variations
were also observed in studies of di-n-butyl phthalate
(DnBP), DnOP, DiNP and DiDP [73], while benzylbutylph-
thalate (BBzP) produced no adjuvant effect [74]. The
authors postulated that the lengths of the carbon side
chains are important in terms of the biological activities in
this respect [73]. Subsequent studies using the intraperi-
toneal route for administration of DEHP and DiNP also
showed adjuvant effects [75,76]. These experiments,
however, do not reflect the actual conditions of human
contact (mainly oral ingestion, inhalation, or topical
contact).
To mimic the actual routes of human contact, animal
models of phthalate exposure via oral, inhalation, or
topical routes were developed. The few reports of oral
exposure to DEHP showed conflicting results, and further
studies were undertaken [2,44]. Topical exposure to high
doses of DEHP, DiNP, di-isohexyl phthalate (DiHP), or BBzP
also failed to alter the serum concentration of IgE, despite
sufficient percutaneous absorption being confirmed with
significantly elevated liver weights [77]. Similar experi-
ments with DEHP showed consistent results [78], while
experiments using high topical doses of BBzP (100 mg)
resulted in a modest elevation in IgG1, but not IgE [79].
Some studies have used inhalation of aerosols. Repeated
exposure to airborne DEHP has been shown to increase the
serum IgG1 level (but not IgE level) and the levels of
inflammatory cells, including eosinophils, lymphocytes, and
neutrophils, in the lung and bronchoalveolar lavage fluid,
but the effect is observed only at very high concentrations
of DEHP [80]. Repeated exposure to airborne MEHP (a major
metabolite of DEHP) has nearly identical adjuvant effects,
but at lower doses than those required for DEHP [81].
Another study showed that a one-time, 60-minute, expo-
sure to airborne MEHP resulted in acute airway irritation
and an increased number of macrophages in the bron-
choalveolar lavage fluid, only at high levels of exposure
[82].
A human study analyzing the response of subjects
allergic to house dust mites challenged with house dust
containing either low or high levels of DEHP was also per-
formed [83]. Although no effect on symptom scores was
noted, challenges with house dust containing low levels of
DEHP increased eosinophil cationic protein, granulocyte-
colony-stimulating factor (G-CSF), interleukin (IL)-5, and
IL-6, whereas challenges with house dust containing high
S32 M.-J. Tsai et al.levels of DEHP decreased G-CSF and IL-6 [83]. These
observations were interesting, but as the authors
acknowledged, the study design used a short-term exposure
protocol that made it difficult to extrapolate to the pattern
of actual environmental exposure [2].
Although the heterogeneity in the study designs,
including routes of administration, exposure times, and
sensitization protocols, makes it difficult to make direct
comparisons, the overall picture of these experimental
studies suggests that several phthalates may have adjuvant
effects on Th2 responses, immunomodulatory effects, or
immunosuppressive effects under different conditions
[1,2,44].
The route and the dose matter. Significant responses are
obtained from subcutaneous or intraperitoneal adminis-
tration, which do not reflect the actual route of human
exposure to phthalates [2]. The results from animal studies
suggest that the levels of phthalates encountered in the
realistic environment do not have an adjuvant effect or
induce allergic lung inflammation, and are therefore
unlikely to be a major factor contributing to the increased
incidence of asthma and allergy in the developed world
[79,80]. Furthermore, most experiments showed only IgG1
responses, with the absence of an IgE response [2,44]. As
allergic diseases in humans are mainly mediated via IgE, the
results from these animal studies are far from clinically
applicable.Mechanistic toxicologic evidence e in vitro studies
Attempts have also been made to address the in vitro
effects of various phthalates on a variety of cells, focusing
on immunologic cells [1,2,44]. It has been demonstrated
that DEHP may enhance differentiation of bone marrow-
derived dendritic cells (BMDC) with an increased antigen-
presenting activity and an increased T-cell proportion in
splenocytes with increased IL-4 production, whereas it may
activate differentiated BMDC at low doses and suppress
differentiated BMDC at high doses, with no significant
changes in antigen-presenting activity [84]. In primary
murine lymph node cells, DEHP and DiNP may enhance IL-4
production [75,85]. Further experiments using a murine
thymoma cell line (EL4) suggested that both DEHP and DiNP
enhanced IL-4 production via stimulation of the binding
activity of the transcription factor NF-AT to the IL-4 gene
promoter [75]. It has also been found that a glycoprotein
isolated from Cudrania tricuspidata Bureau (CTB glyco-
protein) has a strong inhibitory ability towards DEHP-
induced IL-4 production in primary-cultured murine T
lymphocytes [85]. Some studies have also demonstrated the
effects of MEHP on inducing growth arrest and apoptosis of
bone marrow B cells [86e88].
Studies discussing the effects of phthalates on mono-
cytes and macrophages have revealed complex results.
Although a study with primary alveolar macrophages from
rabbits showed that DEHP may potentiate phagocytosis and
the release of lysosomal enzymes [89], another study
demonstrated limited potentiation of phagocytosis and
a potent inhibitory effect of bacteriocidal capacity [90]. A
study using primary human monocytes and neutrophils from
healthy volunteers demonstrated that metabolites of DEHP(MEHP, 2-EH, and phthalic acid) may suppress oxidative
respiratory metabolism and superoxide generation at
a low pH level, whereas these effects were very weak at
a physiological pH level [91]. Using a rather different
approach, monophthalates showed no effect on the
expression of cytokines from monocytic cell line THP-1 and
peripheral blood mononuclear cells (PBMCs), except for
increased IL-4 expression in PBMCs from allergic subjects
treated with MnBP [92]. In an ex vivo study, potentiation of
lipopolysaccharide (LPS)-induced TNF-a production was
noted in primary peritoneal macrophages from mice
treated with subcutaneous BBzP in advance, whereas an
in vitro study demonstrated that BBzP may inhibit LPS-
induced TNF-a production in the murine macrophage cell
line RAW264 [93]. Consistent with the potentially immu-
nosuppressive effects of innate immunity, another study
also demonstrated that some phthalates may inhibit LPS-
induced activation of the IFN-b promoter [94].
Besides affecting gene expression of the immune cells,
phthalates may modulate the inflammatory response
rapidly via a nongenomic cellular mechanism [44]. DEHP
may increase the expression of CD11b, an integrin impor-
tant for adhesion and migration of inflammatory cells from
vessels to the inflammatory site, in primary cultured blood
from both humans and rats within a few minutes [95].
Studies using the RBL-2H3 mast cell line revealed that
DnBP, DiBP, and DEHP potentiated antigen-induced
degranulation through increased mobilization of intracel-
lular calcium ions [96]. Short-term exposure to DEHP and
MEHP was shown to potentiate IgE-medicated histamine
release from primary human basophils cultured from non-
atopic subjects, suggesting a possible adjuvant effect on
the elicitation of allergic responses via nongenomic mech-
anisms [97]. Interestingly, although the role of eosinophils
in the pathophysiology of asthma and allergic disease has
been well documented, and increased eosinophils in the
lung and bronchoalveolar lavage fluid have been demon-
strated in an animal model of exposure to aerosol DEHP, no
in vitro data regarding the direct effects of phthalates on
eosinophils are available to date [44].
There are also few reports addressing the direct effect
of phthalates on airway epithelial cells and their active
involvement in the pathogenesis of asthma. In a concen-
tration range of around 10 to 100 mg/L, some mono-
phthalates (MnBP, MBnP, MnOP, MEHP, MiNP, and MiDP) may
promote production of proinflammatory cytokines IL-6 and
IL-8 from a human airway epithelial cell line (A549),
whereas suppressive effects were noted at higher concen-
trations [98]. A recent study further demonstrated
a complex mechanism of phthalate-associated asthma,
focusing on the role of airway epithelial cells and their
interaction with airway smooth muscle cells in airway
remodeling (Fig. 2) [3]. In this study, human bronchial
epithelial cell lines were treated with BBzP, DEHP, DnBP,
and DEP, and the conditioned media were harvested.
Treatment with various conditioned media increased the
proliferation and migration of bronchial smooth muscle
cells, which were major features in the airway remodeling,
and also increased the expression of many inflammatory
and chemiotaxic factors, including IL-8, CXCL5, CXCL2,
CXCL3, IL-6, intercellular adhesion molecule 1 (ICAM-1),
and IL-1b, in the bronchial smooth muscle cells. Further
Figure 2. Phthalates may contribute to airway remodeling.
Human bronchial epithelial cells treated with phthalates
secrete more IL-8 and RANTES, which increase the proliferation
and migration of bronchial smooth muscle cells and increase
the expression of many inflammatory and chemotaxic factors,
especially IL-8 and CXCL5.
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the airway epithelial cell production of inflammatory
cytokines IL-8 and RANTES, which subsequently induced the
proliferation and migration of bronchial smooth muscle
cells. Moreover, (6)-shogaol, (6)-gingerol, (8)-gingerol, and
(10)-gingerol, which are major bioactive compounds
present in Zingiber officinale, suppressed the phthalate-
induced effects of airway remodeling. This study was
quite unique, not only in demonstrating that inflammatory
cytokines produced by bronchial epithelial cells after
exposure to phthalates contributed to airway remodeling
by increasing the migration and proliferation of human
bronchial smooth muscle cells and promoting the secretion
of various inflammatory and chemiotaxic cytokines from
human bronchial smooth muscle cells, but also in revealing
that ginger may reverse phthalate-induced airway remod-
eling [3]. The detailed mechanisms, however, require
further investigation [3].
Other health effects of phthalates
In addition to asthma and allergic diseases, phthalates have
been associated with many health problems. As a kind of
endocrine disrupter chemical, also known as environmental
hormones, this group of xenobiotic substances is able to
interfere with normal homeostasis and metabolism [45,99].
Great concerns have been raised regarding their anti-
androgenic activity, causing testicular dysgenesis,
decreased sperm concentration and worsened semen
quality, infertility, and decreased testosterone levels
[7,45,100]. Prenatal exposure to phthalates may also result
in preterm delivery, congenital anomaly, decreased ano-
genital distance, hypospadias, and decreased masculine
play behaviors among male infants [4,5,7,45,101,102]. In
females, phthalate exposure is associated with earlypuberty, especially thelarche, endometriosis, adenomyosis,
leiomyoma, and even breast cancer [45,103e105]. Although
early studies focused on the estrogenic activity of phtha-
lates in the pathogenesis of breast cancer, a novel
estrogen-independent oncogenic mechanism of phthalates
in breast cancer, involving the AhR/HDAC6/c-Myc signaling
pathway, has been recognized recently [105]. In addition,
significant mild negative correlations were found between
the levels of serum thyroid hormones (both free T4 and
total T4) and the level of urinary phthalate metabolites in
the urine of pregnant women [15]. Furthermore, recent
studies have also recognized possible associations between
phthalate exposure in children and the development of
autism spectrum disorders, although further extensive
confirmation is warranted [106].
Using the Comparative Toxicogenomics Database, a tox-
icogenomic study analyzing the curated interactions
between 16 phthalates and a variety of genes/proteins
found that the top three phthalate toxicity categories were
cardiotoxicity, hepatotoxicity, and nephrotoxicity, and the
top 20 diseases included cardiovascular, liver, urologic,
endocrine, and genital diseases [6]. The authors concluded
that further studies were needed to confirm the signifi-
cance of the associations, especially the newly-discovered
cardiotoxicity and nephrotoxicity [6].Conclusion
As phthalates are used extensively in our daily life, the
effect of phthalate exposure on health has become an
extremely important issue. In addition to their notorious
endocrine-disrupting activities, their contribution to the
pathogenesis of asthma and allergic diseases has been
gradually recognized in recent years. As mentioned above,
much epidemiologic evidence addresses the relationship
between phthalate exposure and asthma and allergic
diseases. Although conflicting results exist, most experi-
mental studies address the adjuvant effects of phthalates
in immune responses. A recent study directly investigated
the effects of phthalates in airway epithelial cells and the
ensuing cellecell interaction with bronchial smooth muscle
cells, simulating the pathophysiology of airway remodeling
in asthma and inflammatory airway diseases. These data
may assist in elucidating how phthalates induce asthma and
allergic diseases.
Nonetheless, the whole picture is still far from being
totally understood. Most of the studies discussing the health
effects of phthalates are epidemiological studies, and few
experimental studies have been performed. Furthermore,
few studies have addressed the detailed molecular signaling
mechanisms underlying the health effects of phthalates. In
order to confirm the causative effects of phthalates in
various diseases, further investigation, including both in vivo
and in vitro studies, is warranted.Acknowledgments
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